ReviewThoracic cancer2018
Role of circulating tumor DNA in the management of early-stage lung cancer.
Review in Thoracic cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04957433 (Lung Health Check Biomarker Study), which is not on this map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Lung Health Check Biomarker Study
Who cites it
20 citing papers in PubMed.
- The updated role of exosomes in cancer diagnosis and therapy.Discover oncology · 2026Review
- Perioperative changing patterns of systemic immune-inflammatory index (SII) and outcomes in stage I-III non-small cell lung cancer: a retrospective cohort study.Journal of thoracic disease · 2025Article
- Transforming Cancer Care: Genomic Profiling, AI, and Next-Generation Drug Delivery Systems.Current genomics · 2025Review
- Targeted treatments after chemoradiotherapy failure in a patient with relapsed, advanced non‑small cell lung cancer with on‑therapy circulating tumor biomarker monitoring: A case report.Oncology letters · 2023Article
- ctDNA as a novel and promising approach for cancer diagnosis: a focus on hepatocellular carcinoma.EXCLI journal · 2023Review
- Combined SERS Microfluidic Chip with Gold Nanocone Array for Effective Early Lung Cancer Prognosis in Mice Model.International journal of nanomedicine · 2023Article
- Research Progress on Postoperative Minimal/Molecular Residual Disease Detection in Lung Cancer.Chronic diseases and translational medicine · 2022Review
- Early assessment of circulating tumor DNA after curative-intent resection predicts tumor recurrence in early-stage and locally advanced non-small-cell lung cancer.Molecular oncology · 2022Article
- Multiplexed Liquid Biopsy and Tumor Imaging Using Surface-Enhanced Raman Scattering.Biosensors · 2021Review
- Article
- Article
- Profiling Colorectal Cancer in the Landscape Personalized Testing-Advantages of Liquid Biopsy.International journal of molecular sciences · 2021Review
- Blood-based Biomarkers for Early Diagnosis of Lung Cancer: A Review Article.JNMA; journal of the Nepal Medical Association · 2020Review
- Translational Application of Circulating DNA in Oncology: Review of the Last Decades Achievements.Cells · 2019Review
- Next-generation sequencing in liquid biopsy: cancer screening and early detection.Human genomics · 2019Review
- A DNA based visual and colorimetric aggregation assay for the early growth factor receptor (EGFR) mutation by using unmodified gold nanoparticles.Mikrochimica acta · 2019Article
- Are There New Biomarkers in Tissue and Liquid Biopsies for the Early Detection of Non-Small Cell Lung Cancer?Journal of clinical medicine · 2019Review
- The clinical value of circulating tumor DNA detection in advanced non-small cell lung cancer.Translational cancer research · 2019Article
- Methylation of LINE-1 in cell-free DNA serves as a liquid biopsy biomarker for human breast cancers and dog mammary tumors.Scientific reports · 2019Article
- Association of clinical outcomes in metastatic breast cancer patients with circulating tumour cell and circulating cell-free DNA.European journal of cancer (Oxford, England : 1990) · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer is one of the most common cancers and the predominant cause of cancer-related death in the world. The low accuracy of early detection techniques and high risk of relapse greatly contribute to poor prognosis. An accurate clinical tool that can assist in diagnosis and surveillance is urgently needed. Circulating tumor DNA (ctDNA) is free DNA shed from tumor cells and isolated from peripheral blood. The genomic profiles of ctDNA have been shown to closely match those of the corresponding tumors. With the development of approaches with high sensitivity and specificity, ctDNA plays a vital role in the management of lung cancer as a result of its reproducible, non-invasive, and easy-to-obtain characteristics. However, most previous studies have focused on advanced lung cancer. Few studies have investigated ctDNA in the early stages of the disease. In this review, we focus on ctDNA obtained from patients in the early stage of lung cancer, provide a summary of the related literature to date, and describe the main approaches to ctDNA and the clinical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.